Fairchild Andrew T, Salama Joseph K, Wiggins Walter F, Ackerson Bradley G, Fecci Peter E, Kirkpatrick John P, Floyd Scott R, Godfrey Devon J
Department of Radiation Oncology, Duke University Medical Center, Durham, North Carolina; Piedmont Radiation Oncology, Winston Salem, North Carolina.
Department of Radiation Oncology, Duke University Medical Center, Durham, North Carolina; Radiation Oncology Service, Durham VA Medical Center, Durham, North Carolina.
Int J Radiat Oncol Biol Phys. 2023 Mar 1;115(3):779-793. doi: 10.1016/j.ijrobp.2022.09.068. Epub 2022 Oct 23.
We sought to develop a computer-aided detection (CAD) system that optimally augments human performance, excelling especially at identifying small inconspicuous brain metastases (BMs), by training a convolutional neural network on a unique magnetic resonance imaging (MRI) data set containing subtle BMs that were not detected prospectively during routine clinical care.
Patients receiving stereotactic radiosurgery (SRS) for BMs at our institution from 2016 to 2018 without prior brain-directed therapy or small cell histology were eligible. For patients who underwent 2 consecutive courses of SRS, treatment planning MRIs from their initial course were reviewed for radiographic evidence of an emerging metastasis at the same location as metastases treated in their second SRS course. If present, these previously unidentified lesions were contoured and categorized as retrospectively identified metastases (RIMs). RIMs were further subcategorized according to whether they did (+DC) or did not (-DC) meet diagnostic imaging-based criteria to definitively classify them as metastases based upon their appearance in the initial MRI alone. Prospectively identified metastases (PIMs) from these patients, and from patients who only underwent a single course of SRS, were also included. An open-source convolutional neural network architecture was adapted and trained to detect both RIMs and PIMs on thin-slice, contrast-enhanced, spoiled gradient echo MRIs. Patients were randomized into 5 groups: 4 for training/cross-validation and 1 for testing.
One hundred thirty-five patients with 563 metastases, including 72 RIMS, met criteria. For the test group, CAD sensitivity was 94% for PIMs, 80% for +DC RIMs, and 79% for PIMs and +DC RIMs with diameter <3 mm, with a median of 2 false positives per patient and a Dice coefficient of 0.79.
Our CAD model, trained on a novel data set and using a single common MR sequence, demonstrated high sensitivity and specificity overall, outperforming published CAD results for small metastases and RIMs - the lesion types most in need of human performance augmentation.
我们试图开发一种计算机辅助检测(CAD)系统,通过在一个独特的磁共振成像(MRI)数据集上训练卷积神经网络,该数据集包含在常规临床护理期间未被前瞻性检测到的细微脑转移瘤(BMs),从而最佳地增强人类的检测能力,尤其擅长识别小的不明显的脑转移瘤。
2016年至2018年在我们机构接受针对脑转移瘤的立体定向放射外科治疗(SRS)且未接受过先前脑靶向治疗或小细胞组织学检查的患者符合条件。对于接受连续两个疗程SRS的患者,对其初始疗程的治疗计划MRI进行复查,以寻找与第二次SRS疗程中治疗的转移瘤相同位置出现的新转移瘤的影像学证据。如果存在,这些先前未识别的病变被勾勒出来并归类为回顾性识别的转移瘤(RIMs)。根据它们是否符合基于诊断成像的标准(+DC)或不符合(-DC),仅根据其在初始MRI中的表现将RIMs进一步细分,以明确将它们归类为转移瘤。还纳入了这些患者以及仅接受单个疗程SRS的患者的前瞻性识别的转移瘤(PIMs)。采用一种开源的卷积神经网络架构并进行训练,以在薄层、对比增强、扰相梯度回波MRI上检测RIMs和PIMs。患者被随机分为5组:4组用于训练/交叉验证,1组用于测试。
135例患者有563个转移瘤,包括72个RIMs,符合标准。对于测试组,CAD对PIMs的敏感性为94%,对+DC RIMs的敏感性为80%,对直径<3 mm的PIMs和+DC RIMs的敏感性为79%,每位患者的假阳性中位数为2个,Dice系数为0.79。
我们的CAD模型在一个新的数据集上进行训练,并使用单一的常见MR序列,总体上表现出高敏感性和特异性,在小转移瘤和RIMs(最需要增强人类检测能力的病变类型)方面优于已发表的CAD结果。